 |
|
|
|
|
|
NEWS RELEASE:
FOR IMMEDIATE RELEASE:
|
Beth Frost-Johnson, Sr. VP of Marketing
Merge Healthcare
414.977.4254
bfrost@merge.com
|
|
Richard Linden, President and CEO
Merge Healthcare
414.977.4000
rlinden@merge.com
|
|
Merge eMed to showcase innovative Software solutions at Society of Computer Applications in Radiology (SCAR)
Merge eMed showcases powerful 64-bit processing in FUSION Matrix PACS and RIS/PACS solutions that enables users to simultaneously load, view, compare and manipulate more images than ever before.
Milwaukee, WI, April 26, 2006 – Merge Healthcare (NASDAQ: MRGE; TSX: MRG) , a leader in healthcare software and services, today announced that it will showcase its FUSION Matrix PACS 64-bit processing technology at SCAR, April 27-29, in Austin, TX.
Merge eMed continues its innovation with the first PACS application running in a 64-bit environment. The 64-Bit Edition of FUSION Matrix PACS enables radiologists to easily load and manipulate studies regardless of size. With this innovative solution, comparison is possible with as many priors as needed. Performance testing has supported loading more than 10,000 images simultaneously without any erosion of workstation performance. The power of 64-bit far surpasses existing limits on memory usage. When combined with the FUSION RIS, users gain full clinical and business workflow that can substantially accelerate productivity.
"Merge eMed has led the way with RIS/PACS/Clinical Applications, and this 64-Bit Edition leverages our depth of understanding of imaging workflow," says Robert White, Merge eMed President. "As modalities become more sophisticated, our customers require efficient and effective solutions to accommodate their output in ways that accelerate productivity. Our solution has revolutionized the way large studies such as thin-slice CT and breast MR studies can be read and compared with priors. It's innovations like these in our RIS/PACS/Clinical Applications portfolio that differentiate us from our competitors".
FUSION Matrix PACS is part of the Merge eMed RIS, PACS and Clinical Applications portfolio. Demonstrations of the entire product portfolio will be available to SCAR attendees at booth 745, including mammography and PET CT.
# # #
For further information, please contact:
Beth Frost-Johnson, Sr. VP of Marketing
Merge Healthcare
(414) 977-4254
mailto:bethfj@merge-emed.com
Merge Healthcare is a market leader in the development and delivery of medical imaging and information management software and services. Our innovative software solutions use leading-edge imaging software technologies that accelerate market delivery for our OEM customers, while our end-user solutions improve our customers' productivity and enhance the quality of patient care they provide. For additional information, visit our website at www.merge.com.
Merge eMed, a Merge Healthcare company,is focused on accelerating productivity for radiology departments and specialty practices, imaging centers and hospitals. By combining sophisticated RIS, PACS, advanced visualization and clinical imaging applications, Merge eMed delivers integrated end-to-end software solutions and professional services that are transforming the way our customers interact with referring physicians, manage their workflow, position their businesses in their markets and deliver imaging and information services to their customers. For additional information, visit our website at www.merge-emed.com.
Except for the historical information herein, the matters discussed in this news release include forward-looking statements that may involve a number of risks and uncertainties. When used in this press release, the words: guidance, believes, intends, anticipates, expects, and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements based on a number of factors, including, but not limited to, risks in product and technology development, market acceptance of new products and continuing product demand, the impact of competitive products and pricing, ability to integrate acquisitions, unexpected outcomes to any pending or future litigation, changing economic conditions, credit and payment risks associated with end-user sales, dependence on major customers, dependence on key personnel, and other risk factors detailed in filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect any future events or circumstances.
|
Attn: Beth Frost-Johnson
Merge Healthcare
6737 West Washington St.
Suite 2250
Milwaukee, WI 53214
|
|
|
|
|
|
| Except for the historical information herein, the matters discussed in this news release include forward-looking statements that may involve a number of risks and uncertainties. When used in this press release, the words “will,” “believes,” “intends,” “anticipates,” “expects” and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, the forward-looking statements based on a number of factors, including, but not limited to, the uncertainty created by, the adverse impact on relationships with customers, potential customers, suppliers and investors potentially resulting from, and other risks associated with, the changes in the Company’s senior management; costs, risks and effects of the investigation by the Audit Committee of the Board of Directors; the impact of the restatement of financial statements of the Company and other actions that may be taken or required as a result of such restatement; the Company's inability to timely file reports with the Securities and Exchange Commission; risks associated with the Company's inability to meet the requirements of The NASDAQ Stock Market for continued listing, including possible delisting; costs, risks and effects of legal proceedings and investigations, including the informal, non-public inquiry being conducted by the Securities and Exchange Commission and class action, derivative, and other lawsuits; risks in product and technology development, market acceptance of new products and continuing product demand, the impact of competitive products and pricing, ability to integrate acquisitions, changing economic conditions, credit and payment risks associated with end-user sales, dependence on major customers, dependence on key personnel, and other risk factors detailed in the Company’s filings with the Securities and Exchange Commission. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements contained herein to reflect future events, developments, or changed circumstances, or for any other reason.
|
|
|
